Market Trends of Central Nervous System (CNS) Stimulant Drugs Industry
The Attention Deficit Hyperactivity Disorder Segment is Expected to Witness Significant Growth During the Forecast Period
- The attention deficit hyperactivity disorder segment is expected to hold a significant market share in the central nervous system (CNS) stimulant drugs market during the forecast period. Factors such as the rising prevalence of attention deficit hyperactivity disorder among children and adolescents and the easy availability of treatment drugs such as CNS stimulants will likely propel the segment growth during the forecast period.
- For instance, per the data published by the National Health Insurance Corporation of South Korea in March 2023, the number of individuals diagnosed with attention deficit hyperactivity disorder (ADHD) increased in the past few years, reaching 102,322 in 2022. Further, as per the Centers for Disease Control and Prevention (CDC), in 2022, the approximate number of children detected with attention deficit hyperactivity disorder was 6.1 million, with a prevalence rate of 9.4%.
- Additionally, the increasing prescription rate for ADHD treatment using CNS stimulants is expected to contribute to the market growth during the forecast period. For instance, according to the National Health Institute, in July 2023, the prescription of CNS stimulants and ADHD medications rose by 32% among adults aged 18 and above and 12% in children under 17 during 2022-2023. This increase highlights a growing trend in the treatment of ADHD and other related conditions in both age groups. Thus, increasing the prescription rate for ADHD treatment will contribute to the segment growth during the forecast period.
- Therefore, the attention deficit hyperactivity disorder segment is expected to witness significant growth during the forecast period due to the factors, including the rising prevalence of attention deficit hyperactivity disorder.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Witness Significant Growth During the Forecast Period
- During the forecast period, North America is expected to experience significant growth in the central nervous system (CNS) stimulant drugs market.
- The development of the central nervous system (CNS) stimulant drugs market is driven by the high healthcare expenditure, high prevalence of central nervous system diseases, expanding geriatric population, and presence of leading market players in the region. For instance, as per the data published by the Centre for ADHD Awareness Canada (CADDAC) in 2023, ADHD is one of Canada's most common neurodevelopmental disorders, affecting over 1.8 million Canadians. Several clinical trials are ongoing in North America, especially in the United States. More than half of the total neurological disease clinical studies conducted worldwide are in the United States.
- Also, according to a research study published in the British Medical Journal in 2022, approximately 4.1 million United States adults reported prescriptions for CNS stimulant drugs. The same source reported that the growth rate of the total number of prescriptions dispensed was about 96%, and significant percentage increases occurred in adults aged 25 years and older.
- Therefore, owing to the factors above, the growth of the market is anticipated in North America.
Get Analysis on Important Geographic Markets
Download PDF
